Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Menopause ; 21(5): 484-92, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24065139

RESUMEN

OBJECTIVE: Veralipride is a nonhormonal option for the treatment of vasomotor symptoms of menopause. Incidence of adverse events in a Mexican population and drug compliance according to correct use were evaluated. METHODS: We carried out a longitudinal, prospective, and analytical study in Mexican women who received veralipride to treat symptoms of menopause from 2011 to 2012. There were 386 treatment cycles; 272 were assigned to dosing schedule 1, which included 20 days of treatment with 10 days of suspension, and 114 were assigned to dosing schedule 2, which included 5 days of treatment and 2 days of suspension. RESULTS: A total of 57 adverse events were registered during the 386-month treatment. For the 20 × 10 dosing schedule, the highest incidence was observed for anxiety (2.2%), drowsiness, and weakness (1.5%); for the 5 × 2 dosing schedule, the highest incidence was observed for drowsiness (5.3%) and headache (2.6%). The Hamilton Depression Rating Scale was used to assess the presence and severity of depression; improvement was noted. The Unified Parkinson's Disease Rating Scale was used to assess neurological movement disorders; no adverse neurological events were detected. Based on the assessments of both women and physicians, the highest frequency was observed for "very satisfied" (45.5% and 52.3%, respectively), followed by "satisfied" (23.9% and 27.3%, respectively). CONCLUSIONS: Both dosing schedules show acceptable safety profiles for up to 6 months of use when used according to the contraindications in the current prescribing information for standard use (2012) and recent medical literature.


Asunto(s)
Menopausia/efectos de los fármacos , Sulpirida/análogos & derivados , Sistema Vasomotor/efectos de los fármacos , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Menopausia/fisiología , Persona de Mediana Edad , Satisfacción del Paciente , Estudios Prospectivos , Sulpirida/administración & dosificación , Sulpirida/uso terapéutico
2.
Clin Pract ; 1(4): e93, 2011 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-24765393

RESUMEN

Human papilloma virus (HPV) can infect any of the mucosal areas of the body and cause cervical cancer. Until recently, no specific treatments were available for this condition; therefore, any damaged tissue had to be removed or destroyed, which may have presented obstetrical repercussions for some women. Recently, new drugs have been developed that have shown to be effective for the cure of HPV infection. Glycyrrhizinic acid (GA) has shown fewer side effects and its systemic use makes it possible to reach difficult-to-treat lesions. The purpose of this study was to evaluate the clinical outcome of GA to eliminate the epithelial lesion and HPV. We carried out a longitudinal, descriptive study that included women of reproductive age who were diagnosed with HPV associated with low-grade squamous intraepithelial lesion (LSIL). Subjects began treatment based on GA using two routes of administration - systemic (oral) and topical (spray) - with assessments every month to determine the clinical changes of the lesions through colposcopy and Papanicolaou (Pap) smear. Simple statistics were used along with two-tailed Student's t-test; P<0.05 was considered statistically significant before and after treatment. There were 70 eligible patients, of whom 62 fulfilled the inclusion criteria. Age of subjects was 27.8±9.5 years. At the time of the study, 100% of the patients had HPV infection, 40% were associated with LSIL, and only 16% used a barrier contraceptive (condom) method. Resolution was achieved in all patients from 4 weeks of treatment initiation and improvement was achieved in the majority of patients at 12 weeks (74%) (P<0.001). However, there was persistence of LSIL in 27.7% of patients and only one patient progressed to cervical intraepithelial neoplasia (CIN) II. The use of GA proved to be effective in resolving clinical HPV lesions. For cervical lesions with epithelial changes (LSIL), treatment may be required for a longer period as with other drugs used for this infection, as well as monitoring for at least 1 year according to the natural evolution of the disease.

3.
Ginecol Obstet Mex ; 76(8): 450-3, 2008 Aug.
Artículo en Español | MEDLINE | ID: mdl-18798447

RESUMEN

BACKGROUND: Adiponectin is an hormone produced exclusively in adipose tissue, that actively acts in carbohydrate and fat regulation processes. OBJECTIVE: To determine adiponectin levels in a women's group. PATIENTS AND METHOD: Transversal study in 22 amenorrheal women with climacteric symptoms, and without estrogen therapy. There were excluded those with diabetes, hypertension, dislipoproteinemia and obesity. Significant differences among values of adiponectin in perimenopausal and young women during follicular phase of menstrual cycle were analyzed by means of Student t test. RESULTS: Adiponectin concentration in perimenopausal women was 14.1 +/- 8.2 microg/mL (M +/- SD), without meaningful difference compared with young women. CONCLUSIONS: It wasn't significant variation in adiponectin levels compared with normal menstrual cycle women. Further studies are necessary to establish adiponectin effect in postmenopause and its relation with the cardiovascular diseases.


Asunto(s)
Adiponectina/sangre , Perimenopausia/sangre , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad
4.
Ginecol Obstet Mex ; 76(9): 537-41, 2008 Sep.
Artículo en Español | MEDLINE | ID: mdl-18798460

RESUMEN

BACKGROUND: The prevalence of anemia varies from country to country and there is not a trustworthy record. OBJECTIVE: To determine the frequency of anemia in obstetric patients and the association among healthy pregnancy and aggregate complications. PATIENTS AND METHOD: Was carried out as transversal, observational and comparative study. Obstetrical patients entered and responded in the period of a year, were formed a group with normal pregnancy and another with complicated pregnancy, with a total sample of 194 patients. In the statistical analysis was employed Student t test for independent groups, with value if p < 0.05. RESULTS: When was included all patients from both groups of study a general frequency of anemia was found in 22.4%. Hematological stage from group with normal pregnancy was mild anemia in 16.9% and anemia moderated in 4.1% of the cases. The anemia degrees in the group with associated illness and pregnancy were mild anemia in 19.2% and moderated anemia in 4.2%. Not any case was found with severe anemia. The statistical analysis showed difference significant among both groups p < 0.05. The most frequently causes of the obstetrical morbidity were preeclampsia severe (22.6%), type 2 diabetes (13.9%), gestational diabetes (12.2%) and the remainder with other complications that include to the hypertiroidism, rheumatoid arthritis, lupus, asthma and vein deep thrombosis. CONCLUSIONS: Frequency of anemia in this study was greater upon informing in the international literature. The obstetrical complication more frequently relates to diverse anemia degrees were the hypertensive stage during pregnancy. The anemia is presented with greater frequency in pregnancy patients with others associated illness.


Asunto(s)
Anemia/epidemiología , Complicaciones Hematológicas del Embarazo/epidemiología , Adulto , Estudios Transversales , Femenino , Humanos , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA